Financials in USD. Standardized financial statements.
A compact view of how IDEAYA Biosciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $218.71M | $7.00M | $23.39M | $50.93M | $27.94M | $19.54M | $0 | $0 | $0 |
| Revenue Growth? | +3024.4% | -70.1% | -54.1% | +82.3% | +43.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $4.59M | $3.83M | $4.01M | $2.10M | $1.73M | $1.38M | $1.25M | $886,000 | $391,000 |
| Gross Profit? | $214.12M | $3.17M | $19.38M | $48.83M | $26.22M | $18.16M | -$1.25M | -$886,000 | -$391,000 |
| Gross Margin? | +97.9% | +45.2% | +82.9% | +95.9% | +93.8% | +92.9% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $373.43M | $330.14M | $153.81M | $111.33M | $76.48M | $53.50M | $43.03M | $35.53M | $14.05M |
| Operating Income? | -$159.31M | -$326.98M | -$134.43M | -$62.50M | -$50.27M | -$35.34M | -$44.27M | -$36.42M | -$14.44M |
| EBITDA? | -$154.72M | -$270.64M | -$108.95M | -$56.55M | -$48.04M | -$33.11M | -$40.73M | -$33.46M | -$11.47M |
| Income Before Tax | -$113.70M | -$274.48M | -$112.96M | -$58.66M | -$49.76M | -$34.49M | -$41.98M | -$34.35M | -$11.86M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$113.70M | -$274.48M | -$112.96M | -$58.66M | -$49.76M | -$34.49M | -$41.98M | -$34.35M | -$11.86M |
| EPS? | $-1.28 | $-3.36 | $-1.96 | $-1.42 | $-1.41 | $-1.31 | $-1.90 | $-2.41 | $-0.83 |
| Diluted EPS? | $-1.28 | $-3.36 | $-1.96 | $-1.42 | $-1.41 | $-1.31 | $-1.90 | $-2.41 | $-0.83 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality